In a country as vast and diverse as India, the journey of a medicine can be as critical as the medicine itself. For patients dependent on speciality therapies, where precision, temperature control, and timing are non-negotiable, access is often the difference between continuity of care and clinical compromise. Recognising this reality, MrMed, India’s largest online speciality pharmacy, has taken a decisive step forward with the launch of its state of the art Bengaluru cold chain hub, alongside a strategic partnership with global healthcare leader Eli Lilly. Together, these developments signal a significant advancement in strengthening India’s speciality medicine ecosystem.
About MrMed
MrMed is India’s largest online speciality pharmacy, dedicated to improving access to high cost and critical speciality medicines. With a focus on oncology, infertility, nephrology, cardiology, and other complex therapeutic areas, MrMed aims to make speciality care more transparent, accessible, and affordable. The company offers end to end support, from genuine product procurement and patient counselling to reliable cold chain delivery, ensuring high quality care for patients across India.
A critical expansion for speciality healthcare
The newly operational Bengaluru hub is designed to support the safe, seamless distribution of high value and temperature sensitive therapies, including oncology treatments, GLP-1 medications, immunology therapies, and transplant medicines. More than an infrastructure expansion, the hub represents MrMed’s long term vision to build a resilient, technology enabled supply network that ensures patients receive genuine, high quality medicines without delay or degradation.
“This expansion marks an important milestone in our mission to strengthen India’s speciality medicine ecosystem,” said Devashish Singh, Co Founder and CEO, MrMed. “Our partnership with Eli Lilly enables us to reach more patients with life saving therapies, supported by enhanced cold chain capabilities.”
The timing of this initiative is particularly significant. India is witnessing a sharp rise in chronic and lifestyle related conditions, with diabetes and obesity alone affecting over 100 million people. As the prevalence of complex diseases grows, so does the demand for advanced speciality therapies, many of which require strict cold chain management from manufacturer to patient.
Strengthening last mile cold chain reliability
MrMed’s cold chain infrastructure in Bengaluru addresses one of the most persistent challenges in India’s healthcare supply chain, last mile reliability. The hub is already helping reduce delivery timelines within Bengaluru while enabling faster and more dependable dispatches across Karnataka, Tamil Nadu, Telangana, and Kerala. For patients in these regions, this translates into shorter wait times, improved treatment adherence, and greater confidence in accessing advanced therapies.
“Our Bengaluru cold chain hub represents a significant step toward strengthening India’s speciality medicine supply network,” said Saurab Jain, Co Founder and Chief Business Officer, MrMed. “As demand for advanced therapies continues to rise, our priority is ensuring patients receive critical treatments safely, reliably, and on time. Our collaboration with Eli Lilly enhances this effort by combining their global expertise with our expanding distribution capabilities.”
The strategic partnership with Eli Lilly further strengthens the impact of this expansion. As a global leader in innovative healthcare solutions, Eli Lilly brings deep scientific expertise and a strong portfolio of speciality medicines to the collaboration. By aligning with MrMed’s growing distribution network and cold chain precision, the partnership supports improved reach, continuity of care, and access to advanced therapies for patients across India.
Patient safety at the core
At the core of this collaboration is a shared commitment to improving patient outcomes through innovation and supply chain excellence. Temperature sensitive medicines, particularly in oncology and metabolic care, demand rigorous handling protocols. MrMed’s enhanced cold chain capabilities ensure that these therapies maintain their integrity throughout the delivery journey, reinforcing confidence among patients, caregivers, and healthcare providers alike.
The launch also highlights the growing importance of robust cold chain infrastructure in India’s evolving healthcare landscape. As speciality medicines become more central to treatment pathways, logistics and distribution are no longer back end functions. They are strategic enablers of care. MrMed’s investment in advanced cold chain solutions positions the company as not just a pharmacy, but a critical healthcare partner committed to reliability and accountability.
Looking ahead
Beyond infrastructure, MrMed’s approach remains deeply patient centric. The company’s end to end model, from genuine product procurement and transparent pricing to patient counselling and reliable delivery, addresses both the clinical and emotional challenges patients face during complex treatment journeys. By reducing uncertainty and friction, MrMed is helping patients focus on what matters most, recovery and quality of life.
Looking ahead, the Bengaluru hub and the partnership with Eli Lilly are expected to serve as catalysts for further expansion, enabling MrMed to scale its cold chain network and reach more underserved regions. As India’s healthcare needs grow more complex, such collaborations will play a defining role in shaping a more inclusive, efficient, and resilient speciality medicine ecosystem.
MrMed is setting a new benchmark for how advanced therapies are accessed and delivered in India. The company’s latest milestone is not merely about growth. It reflects a commitment to building trust, safeguarding medicine efficacy, and ensuring that life saving therapies reach patients when and where they are needed most.
